The future of cancer treatment is inseparable from the future of antibiotics. Sustaining cancer care requires parallel investment in antibiotics through coordinated funding, novel incentives and partnerships designed around public health impact. #AMR #Antibiotics #CancerCare

At #ICPIC2025, Julia Bielicki shared lessons from GARDP's NeoOBS study and NeoSep1 trial on neonatal sepsis. As newborns are especially vulnerable to #AMR. Our goal is to see this evidence shape antibiotic guidelines that protect the youngest lives.

📺 New Encyclopaedia video! Implementation research studies and overcome barriers that stop health interventions from becoming real-world practice. GARDP's Fernando Pascual Martinez explains why it’s vital for antibiotic R&D. 🔗 Watch: www.youtube.com/watch?v=Lb54...

At the recent workshop organised by the Centre for Science and Environment (CSE), experts from Africa and Asia came together to share perspectives on updating the Global Action Plan on Antimicrobial Resistance (GAP-AMR). GARDP’s key message was clear: access must be at the centre of the new plan.

🆕 @who.int publication to guide the introduction & appropriate use of #antibiotics in countries. Developed by WHO and GARDP as part of SECURE initiative, it offers practical advice on developing detailed plans for introducing an antibiotic into a country. 🔗📘Operational Guidance: bit.ly/42yQQAD

🔬 New update on AntibioticDB! GARDP’s AntibioticDB, an open-access database cataloguing 3,000+ antibacterial agents, has just been updated with 2D compound structures and molecular weights. A valuable tool for researchers working to address #AMR. 🔗 Explore it: antibioticdb.com/AdbCompounds...

GARDP’s Executive Director Dr Manica Balasegaram writes about the urgent need to revive antibiotic R&D in the Financial Times. Without it, patients may survive cancer, only to lose their lives from untreatable infections. 📖 Read the op-ed here (subscriber-only): www.ft.com/content/196f...

Coming up! The EUP OHAMR Kick-off on September 23rd! 🎉 Join the launch event online, we are streaming live from Brussels! See programme and please register here to receive the link 👉 sv-se.eu.invajo.com/event/eupoha... #AMR #antimicrobialresistance #EUPOHAMR

🚀 Exciting news! Registration is now open for #ACC2026- a *FREE* virtual conference co-organized by GARDP & British Society for Antimicrobial Chemotherapy, joined this year by ADVANCE-ID & Mahidol University. 📅 4 & 5 February 2026 Don’t miss out! 🔗Register here: bit.ly/467KGKa

Among the STIs at risk, #gonorrhoea tops WHO’s AMR priority list with worrying resistance to almost every available treatment. We welcome this timely report from Impact Global Health which reflects GARDP's own observations on #AMR advancing faster than product development. 🔗http://bit.ly/46hdSNv

#Sepsis kills 4,000 people in #Switzerland every year and costs the health system over CHF 1bn. With #AMR on the rise, treating sepsis is becoming even harder. 🌍 GARDP works with Swiss and global partners to develop the antibiotics the world needs. 🔗http://bit.ly/46qs9Yh

Hello Jakarta! At the ReAct Asia-Pacific AMR Conference 2025, co-hosted with Indonesia’s Ministry of Health, GARDP’s Abhijit Roy shared our approach to antibiotic R&D and equitable access and showcased our key partnerships in the Asia-Pacific with governments, civil society, industry and academia.

Every 2.8 seconds, someone dies of sepsis. That’s 1 in 5 deaths worldwide. This #WorldSepsisDay, we share 5 key facts about sepsis and 5 actions GARDP is taking with partners worldwide to fight it. 👉 Swipe through. Share it with your network. #Sepsis #AMR #GARDP

🔬 Spotlight on GARDP and IST’s potential new treatment for gonorrhoea! A new analysis presented at the South African AIDS Conference highlights the potential of zoliflodacin, a first-in-class antibiotic being developed by GARDP, for the treatment of gonorrhoea in South Africa.

🍼 “We need antibiotic trials & equitable access for babies.” – Angela Dramowski At yesterday’s Babies & Bugs in Hospitals webinar by Newborn Toolkit, Angela Dramowski shared data on how #AMR impacts newborns. GARDP’s Sally Ellis led the Q&A.

In March 2006, oncologist Hilary Thomas discovered a small lump in her breast. She was diagnosed with breast cancer and suddenly found herself on the other side of the consultation desk.

📢 Happening today Make sure to join our #REVIVE webinar on Overcoming Challenges of Tuberculosis Drug Discovery and Development with @rocklabtb.bsky.social, Dirk Schnappinger and Laura Cleghorn. The webinar will be moderated by @valmizrahi.bsky.social ⏰15:30-17:00 CEST 🔗 bit.ly/41MR5rr

👶💊Our Children’s Antibiotics Project Leader, Sally Ellis will moderate the Q&A at this #WorldSepsisDay webinar. Experts will share rapid-fire insights on AMR in newborns, outbreak detection and hospital infection control. Join us on 📅 9 Sept | 🕐 13h00 UK

We’re looking for a Regulatory Affairs Consultant (Europe) to shape the regulatory roadmap for a treatment targeting serious Gram-negative infections. 📧 Send your CV to [email protected] |⏰ Apply by 15 Sept 2025 Read the ToR here: gardp.org/wp-content/u... #Consultancy #RegulatoryAffairs #AMR

On 9 Sept (15:30-17:00 CEST), leading researchers will come together for a #REVIVE webinar to discuss what makes TB drug discovery so difficult and what could finally move the field forward. 🔗 Register: attendee.gotowebinar.com/register/458... #Tuberculosis #TB #AMR #REVIVE #GARDP

📍From October 8–10, we’ll be in Yokohama for #BioJapan2025, part of the Swiss Pavilion. For GARDP, it’s a chance to connect with people and organizations who share our goal of developing and delivering treatments for drug-resistant infections to those who need them most.

The #NeoSep1 trial is underway to find safer, better antibiotic treatments for newborn sepsis 🩷 Active at 2 sites in South Africa w/ 19 babies enrolled, the trial is part of #SNIPAFRICA, a Penta-led African-European collaboration to improve treatment of severe newborn infections 👉 snip-africa.org

🙏Thanks to everyone who joined our #REVIVE webinar on syphilis treatment and research. For those who missed it (or want to revisit), the full session is now available to watch anytime: www.youtube.com/watch?v=1BD1...

Huge congratulations to DNDi on the Hideyo Noguchi Africa Prize. A wonderful recognition of your tireless work that has changed so many lives.👏

Join @incate.bsky.social next Entrepreneurs session on using a Target Product Profile (TPP) when developing AMR solutions 💡 🔗Register now: bit.ly/45gAcrt

At #TICAD9, we joined Shionogi, Japan and Ministry of Health, Kenya to celebrate efforts toward bringing a Reserve antibiotic to patients in Kenya with serious Gram-negative bacterial infections and few treatment options.

🦠 Bacteriophages - viruses that target bacteria - could complement the efforts of life-saving antibiotics 💊, especially where treatment options are running out. We joined a Global AMR R&D Hub workshop to explore how to make them a real option everywhere. 📄 The report’s out now: bit.ly/47rYEaA

Meet REVIVE🌍, GARDP’s global antimicrobial R&D community & platform connecting researchers, clinicians & innovators. With fresh, high-quality expert-led webinars, curated resources & a global network, REVIVE answers the questions that matter most in antimicrobial R&D. Explore: revive.gardp.org

A recent post shard by our colleagues at @gardp.bsky.social on "Understanding Cross-Resistance": revive.gardp.org/understandin... #AMR #AntimicrobialResistance

Japan commits an additional $1M to GARDP to fight drug-resistant infections bringing its total support to $10M since 2020. This renewed funding will boost R&D efforts to combat drug-resistant infections and expand global access to antibiotics through 2025-26. 🔗 gardp.org/japan-commit... #AMR

In this new Antimicrobial Viewpoint, Ana Cristina Gales warns that using terms like “cross-resistance” and “collateral sensitivity” too broadly could lead to poor clinical decisions. 📖 Read: revive.gardp.org/understandin...

Tuberculosis still kills over a million people a year, but drug development is lagging. At our upcoming REVIVE webinar, experts from the US, UK and South Africa will break down what’s not working and what just might. 📅9 September 2025, 03:30-05:00 PM CEST 📍Online 🔗Save your spot: bit.ly/3J14UMs

🚨New partnership! We’ve joined hands with ECHO India to pilot an #AntibioticStewardship project in two Indian states – Punjab & Andhra Pradesh. Using their “Hub-and-Spoke” model, we’ll bridge knowledge gaps for healthcare professionals in tertiary care and build a strong stewardship community.

In our last REVIVE webinar, scientists shared how medicines once meant for Alzheimer’s, HIV and veterinary care are being reimagined to fight drug-resistant infections. Watch the full conversation here: bit.ly/4opoulw

Syphilis is back on the rise — and so are the risks for newborns. REVIVE will host a webinar with infectious disease experts to unpack what’s driving the resurgence, where the gaps are and what can be done. Register here: bit.ly/454W7BF

🌏The World Economic Forum reports that timely investments in AMR R&D can result in savings of $15 billion in healthcare costs and $35–40 billion in broader socio-economic benefits every year.

It was a real pleasure for our colleagues to connect with so many brilliant minds at the @stihiv2025.org this week. The energy and engagement around STI research, implementation science and evidence-based solutions was truly inspiring.

GARDP & @dndi.org have shared infra, IT & a joint CMC team since 2019. This approach has cut costs, sped up drug development & expanded reach across Latin America, Africa & Asia. Our latest publication shows how this alliance built on a common mission delivers impact. bit.ly/41miU9I

📅 Save the Date: ACC2026 The Antimicrobial Chemotherapy Conference (ACC2026) is coming your way in February 2026! This year, GARDP and British Society for Antimicrobial Chemotherapy are teaming up with ADVANCE-ID and Mahidol University to develop this online conference.

New research! The NeoHoP score, a potential tool to help identify sepsis in newborns, is now published in BMJ Paediatrics Open. Developed using data from South African hospitals in GARDP’s global observational study, with support from SAMRC. 🔗Read the paper: tinyurl.com/bd7ukc89

🌐At the Boao Forum for Asia Global Health Forum 2025 in Beijing, our team joined a global panel on health equity, chaired by Professor Ren Minghui. GARDP’s Peter Beyer shared a core message: “We cannot achieve Universal Health Coverage without addressing AMR. One depends on the other.”

📰 Nikkei has featured our new partnership with Institute of Science Tokyo to develop urgently needed antibiotics. The article highlights Professor Murakami’s research using protein crystallography helping us improve compounds of GARDP. 🔗 tinyurl.com/yvj68a85

🚩An important milestone as GARDP completes its STI prevalence study in Thailand.

📰 The Nikkan Kogyo Shimbun covers GARDP’s new joint research with Institute of Science Tokyo on developing novel antibiotics to address drug-resistant infections. Read the story here : www.nikkan.co.jp/articles/vie...

C-CAMP India’s One Health AMR Challenge 2025, supported by ICARS, is now open for startups, companies & institutions bringing forward AMR solutions. If you're working on game-changing tools or ideas in the #AMR space, do apply by 3 Aug. Open to Indian and eligible global applicants.

🌟GARDP has completed its study on the prevalence of gonorrhoea and chlamydia in Lusaka, Zambia, to get a better understanding of the burden of these STIs. 👏 Many thanks to Centre for Infectious Disease Research in Zambia - CIDRZ in Zambia & the excellent site team👩‍⚕️ #STIs #Gonorrhoea #Chlamydia

Superbugs could cost the world $2 trillion annually by 2050, warns @theguardian.com. But investing now in new antibiotics and equitable access could save millions of lives, and billions in health costs. Read the article here: www.theguardian.com/society/2025...

🩹💊 When lives are on the line, clinicians often reach for antibiotic combos based on in vitro promise. But do they help or harm? In our new #REVIVE Viewpoint, Dr Angela Huttner calls for robust clinical data to back decisions too important to just make a guess. 🔗https://tinyurl.com/44n49bpm

We are thrilled to work alongside @gardp.bsky.social and the Drug Discovery and Development Centre (H3D), University of Cape Town on a project that truly drives innovation for Global Health needs.

From Australia to the UK to Switzerland, researchers are rethinking what old medicines can do. Join REVIVE’s webinar on 22 July (tomorrow), where leading scientists will discuss repurposing drugs meant for other diseases as effective antibiotics. 🗓️ Register here: bit.ly/44A17N4